REFERENCES

1. Qin J, Gong Q, Zhou C, et al. Differential expression pattern of CC chemokine receptor 7 guides precision treatment of hepatocellular carcinoma. Signal Transduct Target Ther. 2025;10:229.

2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.

3. Li M, Cao S, Xu RH. Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades. Cancer Commun. 2025;45:774-88.

4. Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77:1773-96.

5. Thangaraj JL, Coffey M, Lopez E, Kaufman DS. Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell. 2024;31:1327-1343.e5.

6. Moris D, Martinino A, Schiltz S, et al. Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians. CA Cancer J Clin. 2025.

7. Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525-43.

8. Hu Y, Shen ZH. Practice of precision surgery in primary liver cancer. Hepatobiliary Pancreat Dis Int. 2021;20:108-9.

9. Haber PK, Castet F, Torres-Martin M, et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology. 2023;164:72-88.e18.

10. Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293-313.

11. Chan YT, Zhang C, Wu J, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024;23:189.

12. Schwabe RF, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy. J Hepatol. 2020;72:230-8.

13. Arvanitakis K, Mitroulis I, Germanidis G. Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy. Cancers. 2021;13:2899.

14. Suzuki T. The expanding world of tRNA modifications and their disease relevance. Nat Rev Mol Cell Biol. 2021;22:375-92.

15. Zhou JB, Wang ED, Zhou XL. Modifications of the human tRNA anticodon loop and their associations with genetic diseases. Cell Mol Life Sci. 2021;78:7087-105.

16. McCown PJ, Ruszkowska A, Kunkler CN, et al. Naturally occurring modified ribonucleosides. Wiley Interdiscip Rev RNA. 2020;11:e1595.

17. Suzuki T, Yashiro Y, Kikuchi I, et al. Complete chemical structures of human mitochondrial tRNAs. Nat Commun. 2020;11:4269.

18. Huang MH, Peng GX, Mao XL, et al. Molecular basis for human mitochondrial tRNA m³C modification by alternatively spliced METTL8. Nucleic Acids Res. 2022;50:4012-28.

19. Mao XL, Li ZH, Huang MH, et al. Mutually exclusive substrate selection strategy by human m³C RNA transferases METTL2A and METTL6. Nucleic Acids Res. 2021;49:8309-23.

20. Cui J, Liu Q, Sendinc E, Shi Y, Gregory RI. Nucleotide resolution profiling of m³C RNA modification by HAC-seq. Nucleic Acids Res. 2021;49:e27.

21. Schöller E, Marks J, Marchand V, et al. Balancing of mitochondrial translation through METTL8-mediated m³C modification of mitochondrial tRNAs. Mol Cell. 2021;81:4810-4825.e12.

22. Ignatova VV, Kaiser S, Ho JSY, et al. METTL6 is a tRNA m³C methyltransferase that regulates pluripotency and tumor cell growth. Sci Adv. 2020;6:eaaz4551.

23. Zhang LH, Zhang XY, Hu T, et al. The SUMOylated METTL8 Induces R-loop and Tumorigenesis via m3C. iScience. 2020;23:100968.

24. Feng Q, Wang D, Xue T, et al. The role of RNA modification in hepatocellular carcinoma. Front Pharmacol. 2022;13:984453.

25. Ma CJ, Ding JH, Ye TT, Yuan BF, Feng YQ. AlkB homologue 1 demethylates N³-methylcytidine in mRNA of mammals. ACS Chem Biol. 2019;14:1418-25.

26. Wang X, Han Y, Li J, et al. Multi-omics analysis of copy number variations of RNA regulatory genes in soft tissue sarcoma. Life Sci. 2021;265:118734.

27. Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248-62.

28. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-905.

29. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76:1348-61.

30. Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform. 2021;22:bbaa164.

31. Meng Y, Sang Y, Liao J, et al. Single cell transcriptional diversity and intercellular crosstalk of human liver cancer. Cell Death Dis. 2022;13:261.

32. Fujita M, Yamaguchi R, Hasegawa T, et al. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine. 2020;53:102659.

33. Kan RL, Chen J, Sallam T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation. Trends Genet. 2022;38:182-93.

34. Wang B, Wang Z, Zhou Z, et al. Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway. Mol Cancer. 2025;24:97.

35. Tian Y, Xiao H, Yang Y, et al. Crosstalk between 5-methylcytosine and N⁶-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma. Mol Cancer. 2023;22:5.

36. Lentini JM, Alsaif HS, Faqeih E, Alkuraya FS, Fu D. DALRD3 encodes a protein mutated in epileptic encephalopathy that targets arginine tRNAs for 3-methylcytosine modification. Nat Commun. 2020;11:2510.

37. Chen R, Zhou J, Liu L, Mao XL, Zhou X, Xie W. Crystal structure of human METTL6, the m³C methyltransferase. Commun Biol. 2021;4:1361.

38. Lee SA, Lee KH, Kim H, Cho JY. METTL8 mRNA methyltransferase enhances cancer cell migration via direct binding to ARID1A. Int J Mol Sci. 2021;22:5432.

39. Chang Q, Chen P, Yin J, et al. Discovery and validation of bladder cancer related excreted nucleosides biomarkers by dilution approach in cell culture supernatant and urine using UHPLC-MS/MS. J Proteomics. 2023;270:104737.

40. Wang S, Li H, Liu J, et al. Integrative analysis of m3C associated genes reveals METTL2A as a potential oncogene in breast cancer. J Transl Med. 2022;20:476.